Veritone to Hold Second Quarter 2026 Results Conference Call on August 13th

IRVINE, Calif.--(BUSINESS WIRE)-- Veritone, Inc. (NASDAQ: VERI), a leader in enterprise AI and data solutions, today announced the details of its second quarter 2026 financial results conference call.

Veritone will hold a conference call on Thursday, August 13, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time), to discuss its results for the second quarter 2026, provide an update on the business and conduct a question-and-answer session.

To participate, please join the conference call or live audio webcast links or use the following dial-in numbers and ask to be connected to the Veritone earnings conference call. To avoid any delays, please join at least fifteen minutes prior to the start of the call.

• Conference Call
• Live Audio Webcast
• Domestic Call Number: (844) 750-4897
• International Call Number: (412) 317-5293

About Veritone

Veritone (NASDAQ: VERI) is a leader in enterprise artificial intelligence (AI) solutions. Serving organizations in both commercial and regulated sectors, Veritone’s software, services, and industry applications simplify data management, empowering the largest and most recognizable brands in the world to run more efficiently, accelerate decision-making and increase profitability. Veritone’s leading enterprise AI platform, aiWARE™, orchestrates an ever-growing ecosystem of machine learning models to transform audio, video and other data sources into actionable intelligence. By blending human expertise with AI, Veritone advances human potential and drives positive societal change. To learn more, visit www.veritone.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729747857/en/

Company:
Mike Zemetra
Chief Financial Officer
Veritone, Inc.
[email protected]

Investor Relations:
Cate Goldsmith
Prosek Partners
914-815-7678
[email protected]

Source: Veritone, Inc.

You May Also Be Interested In

• Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
• Dr. James Charasika Scholarship for Medical Students Announces 2026 Recipient, Advancing Patient-Centered Care in U.S. Medicine
• Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer